Exagen (NASDAQ:XGN) Given New $10.00 Price Target at BTIG Research

Exagen (NASDAQ:XGN) had its target price dropped by equities researchers at BTIG Research from $15.00 to $10.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price objective points to a potential upside of 204.88% from the company’s previous close.

XGN has been the subject of several other research reports. B. Riley Financial restated a “buy” rating and set a $8.00 target price (down previously from $18.00) on shares of Exagen in a report on Friday, January 30th. Canaccord Genuity Group upped their target price on Exagen from $11.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, October 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Exagen in a research note on Wednesday, January 21st. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Exagen has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

Exagen Trading Up 1.2%

NASDAQ XGN opened at $3.28 on Tuesday. Exagen has a 52 week low of $2.67 and a 52 week high of $12.23. The company has a debt-to-equity ratio of 1.35, a quick ratio of 4.08 and a current ratio of 4.08. The stock’s 50 day moving average price is $5.23 and its two-hundred day moving average price is $8.20. The stock has a market capitalization of $74.32 million, a price-to-earnings ratio of -3.57 and a beta of 1.90.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Truvestments Capital LLC lifted its holdings in Exagen by 109.5% during the 4th quarter. Truvestments Capital LLC now owns 6,169 shares of the company’s stock valued at $38,000 after purchasing an additional 3,225 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Exagen in the first quarter valued at about $25,000. Larson Financial Group LLC bought a new position in shares of Exagen in the third quarter valued at about $105,000. Persistent Asset Partners Ltd bought a new stake in shares of Exagen during the 4th quarter worth about $80,000. Finally, JPMorgan Chase & Co. grew its stake in Exagen by 320,280.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,019 shares of the company’s stock valued at $176,000 after buying an additional 16,014 shares during the last quarter. 75.25% of the stock is owned by institutional investors and hedge funds.

Exagen Company Profile

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.